Sundar PichaiSundar Pichai earned $164M in 2023

T. Andrew Crockett recently stepped down as the CEO of KalVista Pharmaceuticals, a biotech company, after leading it since 2016. His career in the pharmaceutical industry spans various roles including senior management positions in companies both in the U.S. and...

Quick Links
K

T. Andrew Crockett

Ex-CEO of KalVista Pharmaceuticals

Sector of Economy

Healthcare

CEO of KalVista Pharmaceuticals for

2 years 11 months (Mar 2021 - Mar 2024)

Previous Experience

Unknown

Rivals

Competitors/colleagues of T. Andrew Crockett

Holdings

See how much did T. Andrew Crockett make over time.

During his time as CEO of KalVista Pharmaceuticals, T. Andrew Crockett built a significant stake in the company, holding over 565,000 shares at one point. This represented about 3.1% of the total shares, highlighting his vested interest in the company’s...

Loading...

Total Stock Sold

$5.37M

KALV

$5.37M

323,156 KALV shares

What if they kept their stock?

If T. Andrew Crockett didn't sell their stock, today they would have:
Extra KALV323,156 shares worth $4.18M.
This is -22.11% and $1.19M less than what they got when they sold the stock.

Charitable Transactions

KALV

21,750 shares

KALV

Recent Charitable Transactions

KALV

8,000 shares

KALV

Oct 30, 2023

Charity

KALV

6,500 shares

KALV

Sep 2, 2022

Charity

KALV

4,750 shares

KALV

May 26, 2021

Charity

KALV

6,000 shares

KALV

Jan 4, 2021

Charity

KALV

3,000 shares

KALV

Apr 29, 2020

Charity

Insider Trading

See recent insider trades of T. Andrew Crockett.

KALV

$351.29K

KALV at $14.11/share

Feb 17, 2024

Sale

KALV

$875.88K

KALV at $15.01/share

Feb 14, 2024

Sale

KALV

122,500 shares

KALV

Feb 11, 2024

Received

KALV

$164.95K

KALV at $16.49/share

Feb 1, 2024

Sale

KALV

$360.45K

KALV at $12.02/share

Dec 27, 2023

Sale

KALV

$121.85K

KALV at $8.23/share

Nov 17, 2023

Sale

KALV

8,000 shares

KALV

Oct 30, 2023

Charity

KALV

$159.60K

KALV at $10.73/share

Aug 17, 2023

Sale

KALV

$57.08K

KALV at $10.14/share

Jan 11, 2023

Sale

KALV

$51.32K

KALV at $7.66/share

Feb 17, 2023

Sale

Compensation History

See how much did T. Andrew Crockett make over time.

In 2023, T. Andrew Crockett’s total compensation reached around $3.6 million, making it a high point in his six-year tenure at KalVista Pharmaceuticals. His pay structure mainly consisted of a base salary of $635,200 and a generous bonus of $266,805, which was tied to the company’s performance and his personal contributions. Unlike many of his peers in the biotech sector, Crockett did not receive stock awards or opt for stock options, focusing instead on cash compensation. This approach reflects a strategy that prioritizes immediate results and cash flow. The compensation philosophy was geared towards aligning executive pay with the company's performance, motivating leadership to perform well amid fluctuating market conditions. Despite his impressive earnings, there were no stock awards that vested in 2023, indicating a focus on continuing solid cash performance rather than stock incentive strategies.

Year

2023

Total Compensation

$914.61K

Salary

$635.20K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate executives through competitive compensation packages that align with company performance and individual contributions.

Bonus

$266.81K

Board Justification

The bonus represents the annual cash discretionary bonuses earned by Mr. Crockett pursuant to the achievement of certain Company and individual performance objectives for the fiscal year 2023.

Other

$12.60K

Board Justification

This includes Company contributions to the 401(k) Plan and other benefits.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the focus is on cash compensation and performance bonuses.

Performance Metrics

The performance metrics for determining Mr. Crockett's compensation included individual performance objectives and overall company performance.

Other KalVista Pharmaceuticals CEOs

Here are other CEOs of KalVista Pharmaceuticals